Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related neurodegenerative deficits.

Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related neurodegenerative deficits.

Publication date: Oct 11, 2024

One key limitation in developing effective treatments for neurodegenerative diseases is the lack of models accurately mimicking the complex physiopathology of the human disease. Humans accumulate with age the pigment neuromelanin inside neurons that synthesize catecholamines. Neurons reaching the highest neuromelanin levels preferentially degenerate in Parkinson’s, Alzheimer’s and apparently healthy aging individuals. However, this brain pigment is not taken into consideration in current animal models because common laboratory species, such as rodents, do not produce neuromelanin. Here we generate a tissue-specific transgenic mouse, termed tgNM, that mimics the human age-dependent brain-wide distribution of neuromelanin within catecholaminergic regions, based on the constitutive catecholamine-specific expression of human melanin-producing enzyme tyrosinase. We show that, in parallel to progressive human-like neuromelanin pigmentation, these animals display age-related neuronal dysfunction and degeneration affecting numerous brain circuits and body tissues, linked to motor and non-motor deficits, reminiscent of early neurodegenerative stages. This model could help explore new research avenues in brain aging and neurodegeneration.

Open Access PDF

Concepts Keywords
Alzheimer Aging
Healthy Animals
Models Brain
Neurodegeneration Catecholamines
Rodents Catecholamines
Disease Models, Animal
Female
Humans
Male
Melanins
Melanins
Mice
Mice, Transgenic
Monophenol Monooxygenase
Monophenol Monooxygenase
Neurodegenerative Diseases
neuromelanin
Neurons
Pigmentation

Semantics

Type Source Name
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
drug DRUGBANK Ribostamycin
drug DRUGBANK L-Tyrosine
pathway REACTOME Metabolism
drug DRUGBANK Dopamine
drug DRUGBANK Norepinephrine
disease MESH sleep disorders
disease MESH anxiety
drug DRUGBANK Flunarizine
drug DRUGBANK Tricyclazole
drug DRUGBANK Isoxaflutole
disease MESH impaired olfaction
disease MESH death
pathway REACTOME Release
disease MESH depression
disease MESH shock
disease MESH astrocytosis
drug DRUGBANK Acetylcholine
drug DRUGBANK Serine
drug DRUGBANK Serotonin
disease MESH immobilization
drug DRUGBANK L-Phenylalanine
disease MESH pathogenesis
pathway REACTOME Autophagy
disease MESH alpha synuclein pathology
disease MESH REM sleep behavior disorder
disease MESH gait
disease MESH cognitive impairment
disease MESH Lewy body disease
disease MESH posture
drug DRUGBANK Coenzyme M
pathway REACTOME Translation
drug DRUGBANK Water
pathway REACTOME Reproduction
drug DRUGBANK Isoflurane
drug DRUGBANK Oxygen
drug DRUGBANK Tretamine
drug DRUGBANK Etodolac
drug DRUGBANK Methotrexate
drug DRUGBANK Pentobarbital
drug DRUGBANK Phosphate ion
drug DRUGBANK Sucrose
drug DRUGBANK Benzyl alcohol
drug DRUGBANK Benzyl Benzoate
pathway REACTOME Acetylation
drug DRUGBANK Trolamine
drug DRUGBANK Levamisole
drug DRUGBANK Citric Acid
drug DRUGBANK Tromethamine
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Biotin
drug DRUGBANK Abacavir
drug DRUGBANK Silver nitrate
drug DRUGBANK Ethanol
disease MESH Disease Models Animal

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *